COVID-19 and Its Impact on Upper Gastrointestinal (GI) Cancer Management

COVID-19 and Its Impact on Upper Gastrointestinal (GI) Cancer Management

Coronavirus disease 2019 (COVID-19), caused by the novel, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, has left dramatic footprints on human health and economy. Cancer, whilst not an infective disease, is prevalent in epidemic proportions and cannot be pretermitted due to the...

Full description

Bibliographic Details
Main Authors: Shalini Fernando, Mesel Veli, Borzoueh Mohammadi, Andrew Millar, Khurum Khan
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Cancers
Subjects:
gastrointestinal
cancer
coronavirus
endosocopy
COVID-19
SARS-Cov-2
Online Access:https://www.mdpi.com/2072-6694/13/3/397
Description
Summary:Coronavirus disease 2019 (COVID-19), caused by the novel, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, has left dramatic footprints on human health and economy. Cancer, whilst not an infective disease, is prevalent in epidemic proportions and cannot be pretermitted due to the impact of COVID-19. As we emanate from the second national lockdown in the UK with mixed feelings of hope and despair—due to vaccination and new COVID-19 variant, respectively—we reflect on the impact of the first wave on the provision on diagnosis and management of with upper gastrointestinal (UGI) cancers. This review provides a critical analysis of available literature on COVID-19 and its impact on cancer management in general and that of UGI cancers in particular.
ISSN:2072-6694

Similar Items